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Abstract
Background: Platelet-activating factor (PAF) has been long believed to be associated with many pathophysiological
processes during septic shock. Here we present novel activities for PAF in protecting mice against LPS-mediated endotoxic
shock.
Principal Findings: In vivo PAF treatment immediately after LPS challenge markedly improved the survival rate against
mortality from endotoxic shock. Administration of PAF prominently attenuated LPS-induced organ injury, including
profound hypotension, excessive polymorphonuclear neutrophil infiltration, and severe multiple organ failure. In addition,
PAF treatment protects against LPS-induced lymphocytes apoptosis. These protective effects of PAF was correlated with
significantly decreases in the production of the inflammatory mediators such as TNF-a, IL-1b, IL-12, and IFN-c, while
increasing production of the anti-inflammatory cytokine IL-10 in vivo and in vitro.
Conclusions: Taken together, these results suggest that PAF may protect mice against endotoxic shock via a complex
mechanism involving modulation of inflammatory and anti-inflammatory mediators.
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Introduction
Sepsis is a serious and complex clinical syndrome caused by an
overly active host response to infection. sepsis develops in 750,000
people annually, with more than 210,000 cases resulting in death
in the United States alone[1]. Under normal conditions, in
response to microbial challenge, an immunocompetent host
initiates an immediate robust response to constrain and clear the
pathogen. However, if the infection is not controlled and spreads
beyond the local site, the systemic inflammatory response becomes
hyperactive. This pervasive immune response often results in such
detrimental complications as multiple organ failure, profound
hypotension, and immune paralysis, all of which contribute to the
high mortality observed in severe sepsis.
Lipopolysaccharide (LPS) is responsible for initiating this
process by inducing the uncontrolled release of proinflammatory
mediators from immune cells, particularly monocytes and
macrophages. Major proinflammatory cytokines produced during
an infection, including tumor necrosis factor (TNF)-a, interleukin
(IL)-1b, interferon (IFN-c), and IL-12, play a prominent roles in
defective activation of the host immune response and sepsis-
induced tissue injury [2–5].
Platelet-activating factor (PAF; 1-O-alkyl-2-(R)-acetyl-sn-glycer-
yl-3-phosphonocholine) is a potent phospholipid mediator of many
leukocyte functions with diverse biological activities [6,7]. In
addition to its role as a physiological mediator, PAF has been
associated with the pathology of endotoxic shock. Further,
previous studies show that the blood PAF level increased during
endotoxemia and that the administration of PAF antagonists in
animals protects them from the deleterious effects of endotox-
in[8,9]. For this reason it was postulated that an agent which
antagonizes PAF activity may have therapeutic value. However,
clinical trials involving administration of PAF receptor (PAF-R)
antagonists failed to demonstrate efficacy in diseases such as septic
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studies involving PAF antagonists have produced conflicting
results, with some showing improvement in hemodynamic profile
and survival, while others not showing any significant differences
at all [10]. Interestingly, Walterscheid et al. [11] suggested that
PAF plays a critical role in systemic immune suppression induced
by the environmental immunotoxin, UV radiation. However,
despite extensive investigation, the precise role of PAF among a lot
of inflammatory mediators in the development of sepsis still
remains largely unknown. In this report, we demonstrate novel
pathophylsiological activities of PAF in LPS-induced endotoxemia.
PAF provided marked therapeutic activity concomitant with early
downmodulation of proinflammatory cytokines and induction of
the antiinflammatory cytokine IL-10.
Results
PAF protects mice from LPS-induced endotoxemia
To assess the importance of PAF in protection against
endotoxemia, a well-established experimental animal model for
endotoxic shock was used. BALB/c mice injected intraperitoneally
with a lethal dose LPS (20 mg/kg) nearly died within 36 h of
challenge (Figure S1). To determine whether PAF could improve
survival in these mice, animals were injected intraperitoneally with
vehicle alone or varying doses of PAF immediately after LPS
challenge and then monitored for 6 d. PAF significantly improved
the mortality of these mice in a concentration-dependent manner
starting at the 1 mg dose (Figure 1A).
Next, we examined whether inhibition of PAF-R activation by
BN-52021, a PAF-R specific antagonist, could directly affect the
protective effects of PAF. In these experiments, animals were
treated with vehicle alone, BN-52021, PAF, both compounds
immediately after LPS challenge. As controls, mice were also
administered with BN-52021 or PAF alone without LPS challenge.
Although the mortality of endotoxemic mice that received BN-
52021 were slightly delayed compared to those treated with
vehicle alone, treatment with the PAF-R antagonist blocked the
protective effects of PAF against LPS-induced lethality (Figure 1B).
To evaluate the efficacy of therapeutic treatment (postchallenge)
of PAF in preventing of mortality, mice were administered PAF
3 h and 6 h after LPS challenge. A kinetic study revealed that
PAF-mediated protection of mice form lethal endotoxemia was
substantially reduced when PAF treatment was delayed up to 3 h
post-LPS injection (Figure 1C).
Reports have shown that PAF activity is abolished by PAF
acetylhydrolase[12]. Carbamyl-PAF (cPAF), an analogue of PAF,
is more metabolically stable and capable of maintaining PAF
activity for longer durations. Therefore, we assessed the effect of
sustained PAF activity on mortality in LPS-induced endotoxemic
mice by administering identical doses of cPAF (1 mg/mouse) or
PAF (1 mg/mouse) immediately after LPS challenge. There was no
difference between the numbers of mice that developed endotox-
emia in LPS-induced endotoxemic mice group administrated with
PAF and cPAF (0 of 10 vs. 3 of 10, respectively; p.0.05).
Therefore, cPAF administration was also resistant to LPS-induced
lethality (Figure 1D).
Alteration of LPS-induced inflammatory cytokine
production by PAF treatment
Endotoxic shock is mediated by an excessive production of
proinflammatory cytokines such as TNF-a, IL-1b, IL-6, IL-12 and
IFN-c[13–15]. To demonstrate the effect of PAF on LPS-induced
inflammatory cytokines production, serum levels of these cytokines
following PAF administration in LPS-challenged mice were
analyzed. At the 2 h time point, high concentrations of
proinflammatory cytokines including IL-12p70, IL-6, IL-1b, and
TNF-a were detected in sera. IFN-c was also significantly
increased 6 h after LPS challenge. However, the levels of these
cytokines were reduced significantly by PAF treatment in a dose-
dependent manner. Interestingly, IL-10, an anti-inflammatory
cytokine, was notably elevated by PAF treatment in LPS-
challenged mice (Figure 2A)
Figure 1. Effect of PAF on the survival rate of LPS-induced
endotoxemic mice. (A) Survival of mice i.p. with varying doses of PAF
(0.1 to 5 mg/mouse) following LPS challenge (20 mg/kg,) was moni-
tored for 6 d. Shown is one of six experiments with similar results. (B)
Treatment with PAF-R antagonist, BN-52021 (80 mg/mouse, i.p), blocked
the protective effect of PAF (2.5 mg/mouse) against lethality. (C)
Delayed treatment of PAF (5 mg/mouse) had no protective effect
against LPS-induced lethality. (D) Effect of cPAF (1 mg/mouse) on
survival. N=8–10 mice per group. *P,0.05; **P,0.001 compared with
LPS challenge.
doi:10.1371/journal.pone.0006503.g001
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PLoS ONE | www.plosone.org 2 August 2009 | Volume 4 | Issue 8 | e6503Figure 2. Effects of PAF on LPS-induced inflammatory cytokine production. (A) Mice were injected with vehicle alone (PBS containing 0.25%
BSA), or LPS (20 mg/kg, i.p.), or PAF (0.1–5 mg/mouse) immediately following LPS challenge. Blood was collected at 2 h or 6 h (for INF-c measurement)
after injection. PAF treatment altered the serum level of different cytokines in response to LPS in a dose-dependent manner. The mean6SEM values
shown represent three independent experiments. *P,0.05; **P,0.001 compared with LPS challenge. (B) Peritoneal macrophages were isolated 3 d
following i.p. injection with 2 ml of 4% thioglycollate. Macrophages were then incubated with LPS alone (100 ng/ml) or a combination of LPS and PAF
(0.4 mM) for 3 h or 6 h. (C) BMDCs were generated from murine bone marrow cells as described in the Materials and Methods section. BMDCs were
stimulated with LPS(100 ng/ml) in the presence of PAF (0.4 mM) for the indicated times. Cytokines concentrations in culture supernatants were
measured in triplicate by ELISA. The mean6SEM values shown represent three independent experiments. *P,0.05; **P,0.001.
doi:10.1371/journal.pone.0006503.g002
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cytokines in immune response. As such, we investigated whether
PAF could directly suppress cytokines production in LPS-stimulated
macrophages and DCs. PAF treatment of LPS-stimulated perito-
neal macrophages remarkable changes in certain cytokine levels.
For example, TNF-a, IL-6, and IL-12p70 were decreased, whereas
IL-10 was increased substantially compared to that in macrophages
stimulated by LPS alone (Figure 2B). Similar to the results obtained
from macrophages, TNF-a and IL-12p70 production induced by
PAF treatment were decreased, whereas IL-10 was increased
significantly compared to that in bone-marrow derived DCs
(BMDCs) compared to LPS stimulation alone (Figure 2C). We
already identified that PAF-R expression in DCs was induced by
LPS or PAF (Figure S2). Unlike macrophages, however, IL-6 was
decreased marginally at 6 h (Figure 2C).
Administration of PAF attenuated LPS-induced organ
injury
Because polymorphonuclear neutrophils (PMNs) infiltration
into the major organs such as the lung and liver significantly
correlates with the severity of inflammation and is a hallmark of
endotoxemia, the effect of PAF treatment on PMN infiltration on
these tissues was examined histologically. The lungs of mice
injected with PAF alone appeared normal with no observable
differences compared to vehicle-treated mice. Mice injected with
LPS alone, however, exhibited massive of PMN infiltration into
interstitial spaces, marked thickening of the alveolar septa, and
pulmonary edema in lung tissue (Figure S3). However, these
changes were significantly attenuated in endotoxemic mice treated
with PAF (Figure 3A). Similar to the lung, PAF treatment reduced
PMN infiltration in the liver (Figure S4). Myeloperoxidase (MPO)
is abundant in azurophilic granules of PMNs and its expression
level is often used as a measure of PMN recruitment. To quantify
the degree of PMN infiltration into lung and liver tissue, MPO
activity was assessed. Consistent with the histological changes
observed in these tissues, the LPS-mediated increase in MPO level
were decreased following PAF treatment, indicating attenuated
PMN recruitment (Figure 3B).
Since endotoxemia frequently causes life-threatening inflamma-
tory condition that involves multiple organ injury and dysfunc-
tion[16], we examined the effect of PAF administration on LPS-
induced organ damages by measuring serum levels ALT and AST,
which reveal liver function, and BUN, measurement of renal
function. Serum ALT and AST levels in mice injected with both
PAF and LPS was lower than those in LPS-challenged mice. In
addition, the LPS-induced BUN level was significantly reduced by
PAF (Figure 3C). In mice treated with vehicle or PAF alone, liver
and renal function tests were substantially unchanged. These
results indicated that LPS-initiated organ injury was conspicuously
ameliorated by PAF administration.
Hypotension is a clinical characteristic of severe sepsis and plays
an important role in the pathophysiology of septic shock and
multiorgan failure syndrome. To assess effect of PAF on the
regulation of vasculature function during LPS-induced endotox-
emia, we measured the mean arterial blood pressure (MABP) in
mice with this condition. Although intraperitoneal injection of
PAF alone initially demonstrated a potent hypotensive effect, the
MABP gradually returned to normal within 50 min post-injection.
In contrast to the rapid drop observed during endotoxic shock, the
drop in MABP of endotoxemic mice injected with PAF was
delayed and sustained at near normal levels for at least 5 h
(Figure 3D). Nitric oxide, a major mediator of hypotension, was
also analyzed in blood collected 20 h after administration of
vehicle alone, PAF, LPS or PAF plus LPS. While serum nitrite
levels were elevated with LPS challenge alone, these levels were
decreased appreciably when mice were also treated with PAF
(Figure 3E). These results strongly indicate that PAF treatment
attenuates LPS-induced organ injury.
PAF protects against lymphocytes apoptosis
Recent several studies have demonstrated that lymphocyte
apoptosis may be detrimental during sepsis due to the depletion of
lymphocytes that essential for defense against invading microor-
ganisms [5,17,18]. We examined that the effect of PAF on
lymphocytes apoptosis induced by endotoxemia. LPS challenged
mice showed a dramatic increase in TUNEL positive cells that was
significantly reduced with PAF treatment (Figure 4A). The
protective effect of PAF on endotoxin-induced lymphocyte
apoptosis was also confirmed by hematoxylin and eosin staining,
which illustrated the morphological changes in cells undergoing
apoptosis in LPS challenged mice. Consistent with previous
reports[18], apoptotic cells in the spleen of LPS-challenged mice
possessed small and compact nuclei (pyknosis) with multiple
nuclear fragments (apoptotic bodies). However, cells from PAF
administered-mice had less nuclear contraction and fragmentation
(Figure 4B). Flow cytometry with Annexin V staining also
demonstrated that a lethal dose of LPS caused a marked increase
in T and B cells apoptosis. However, consistent with the findings
obtained from the TUNEL and hematoxylin and eosin staining,
PAF administration prevented apoptosis in these cells (Figure 4C).
Finally, no apparent apoptosis was observed in the spleen of mice
administered with PAF alone.
Discussion
This study demonstrated the protective effect of exogenous PAF
administration against LPS-induced endotoxemia and identified
the molecular mechanisms involved in this biological process.
Contrary to previous pharmacologic reports concerning the role of
PAF in inflammation, our results demonstrate that mice treated
with PAF acquired resistance to LPS-induced endotoxic shock,
and that this effect can be blocked by the PAF-R antagonist BN-
52021 (Figure 1A, B). Although no therapeutic activity was
observed until PAF treatment was delayed to 6 h after LPS
challenge, treatment with PAF before or immediately after a lethal
LPS dose protected mice against endotoxic death (Figure 1C).
These results challenge the current paradigm of PAF as an
important mediator of sepsis, which is based on the concept that
septic shock results from an uncontrolled inflammatory response.
For many years, studies on the biological effects of PAF as a potent
inflammatory mediator were mainly been focused on the
activation of cells involved in inflammation. Thus, many clinical
trials for severe sepsis attempted to inhibit the action of PAF with a
variety of PAF-R antagonists. Although septic animal models
exhibit beneficial effects as a result of PAF antagonist treatment,
clinical studies on patients with sepsis do not display similar
outcome. Because the dose of PAF-R antagonists which inhibit
endotoxin-induced sepsis are typically more than 10-fold higher
than those for PAF released during sepsis, it is suggests that
protective effect of PAF antagonist may be related in non-specific
inhibition [19]. Study using PAF-R deficient mice further verified
these points. Ishii S et al [19] observed no significant differences in
lethality and production of inflammatory cytokines during
endotoxic shock between wild-type and PAF-R-deficient mice,
implying that PAF is not essential for endotoxic shock develop-
ment. Recently, Walterscheid et al [11] provided evidence for a
novel immunoreglatory role for PAF, which, in addition to being a
sensor for cellular damage, can activate immune suppressive
Effect of PAF on Endotoxemia
PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6503Figure 3. Effect of PAF treatment on organ injury induced by LPS. (A) Lung sections, as well as sera, were obtained from mice 20 h after
treatment with vehicle alone, PAF (5 mg/mouse), LPS (10 mg/kg) or LPS plus PAF. Lungs were perfused and fixed with formalin, and sections of lung
were stained with hematoxylin and eosin. Shown are representative images of lung sections from each group of mice. (B) The MPO level in the liver,
lung, and kidney from each group of mice was assessed 20 h post-injection. (C) The amounts of AST, ALT, and BUN in the sera were measured. The
mean6SEM values shown represent three independent experiments. *P,0.05; **P,0.001. (D) Changes in MABP were measured in animals injected
with PAF (5 mg/mouse, i.p.), LPS (10 mg/kg, i.p.), or PAF plus LPS. The data points indicate the mean MABP of mice for the 10 min. Results are
expressed as a percentage of baseline6SEM. The baseline was set to the mean value over a 10 min period before injection at time 0. The basal MABP
of mice were 76.265.7 mmHg. Numbers in parentheses are the numbers of animals alive at the indicated times. MABP of dead mice was taken to be
zero. (E) PAF inhibits nitric oxide production in LPS-challenged mice. Blood samples were collected 20 h after treatment with vehicle alone, PAF
(5 mg/mouse), LPS (10 mg/kg) or LPS plus PAF, and serum nitrite levels were measured by chemiluminescence assay. Data are presented as the
mean6SEM of five independent experiments. *P,0.001 compared with LPS-challenged mice group.
doi:10.1371/journal.pone.0006503.g003
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PLoS ONE | www.plosone.org 5 August 2009 | Volume 4 | Issue 8 | e6503Figure 4. Exogenous PAF prevents lymphocyte apoptosis in LPS-induced endoxemia. BALB/c mice (7 wk old, n=3) were injected with
either vehicle alone, PAF (5 mg/mouse, i.p.), LPS (10 mg/kg, i.p.), or both and sacrificed after 20 h. (A) Apoptotic cells fluorescently labeled using the
TUNEL assay. Fixed paraffin-embedded spleens were labeled using the TUNEL assay to detect apoptotic cells and then examined by laser scanning
confocal microscopy at magnifications of6100. (B) Hematoxylin and eosin staining, which illustrated the morphological changes (compacted and
fragmented nuclei) in cells undergoing apoptosis, revealed splenocytes from endotoxic mice underwent extensive apoptosis while spleen from
endotoxic mice treated with PAF did not. (C) Flow cytometric analysis of apoptosis. Splenocytes from each group of mice were examined for
apoptosis by flow cytometry using Annexin V staining. T and B cells were distinguished by staining with PE-conjugated anti-CD3 and anti-CD19 Abs,
respectively. LPS-induced endotoxemia increased apoptosis in both cell types, while PAF protected them against endotoxemia-induced cell death.
The mean6SEM values shown represent three or four independent experiments. *P,0.05 compared with LPS-challenged mice group.
doi:10.1371/journal.pone.0006503.g004
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suggesting that the beneficial effect of exogenous PAF occurred
primarily by interference with the cascade of events ultimately
leading to the onset of severe endotoxin shock.
Sepsis is just one example of a pathologic condition associated
with a cytokine storm, the excessive and sustained production of
numerous cytokines by immune cells. Much evidence derived from
studies in animal and in human systems show that highly elevated
levels of proinflammatory cytokines contribute to high mortality by
septic shock [2,4]. Our results demonstrate that, in addition to
protecting against endotoxin-mediated high mortality, PAF induces
remarkable changes in the production level of cytokines in response
to LPS. In particular, two distinct patterns were observed. First, in
LPS-induced endotoxemic mice, PAF administration resulted in
prominent decrease in the production of circulating proinflamma-
tory cytokines, including TNF-a, IL-1b, IL-12p70, and IFN-c
(Figure 2). Second, PAF administration significantly increased
production of the compensatory anti-inflammatory cytokine IL-10
(Figure 2). Because anti-inflammatory cytokines are released as a
regulatory mechanism in septic shock and several studies using
animal models of sepsis have demonstrated that recombinant IL-10
has a protective effect against mortality and proinflammatory
cytokine production [20–23], it is possible that augmented IL-10
production by PAF may contribute to a compensatory response
during endotoxin shock. And also, we observed that PAF-mediated
protection of mice from lethal endotoxemia could be blocked by
prior administration of neutralizing anti-IL-10 antibodies, but not
by an isotype control antibody (J.Y.I., unpublished observation).
These resultsimplicatethat IL-10,asone ofmechanisms involved in
the capacity of PAF to protect mice from LPS-induced toxic shock,
confers partially on systemic immune suppression.
Exaggerated proinflammatory cytokines activity can result in
symptoms of septic shock. Specially, TNF-a and IL-1b contributed
to the increase in the number of infiltrating neutrophils which play a
critical role in bacterial clearance[24]. Our data demonstrate that
after LPS challenge, massive PMN infiltration in the lung and liver
was promoted (Figure 3A). In addition, the level of lung, liver,
kidney MPO was increased (Figure 3B). Interestingly, histological
examination of liver and lung sections showed that PMN
accumulation in PAF-administrated mice were significantly lower
than those in LPS-challenged mice. Correspondingly, there was a
trend toward a decrease in MPO levels in the lung, liver, kidney of
PAF-treated endotoxemic mice. By analyzing serum biochemical
parameters that assess liver damage (AST/ALT) and renal function
(BUN), we found that PAF treatment significantly reduced levels of
tissue damage following LPS administration (Figure 3C). Severe
hypotension is an important hallmark of endotoxic shock and has
been linked to iNOS expression and excessive NO production.
Coincident with alleviation of LPS-induced hypotension, PAF
treatment markedly reduced NO production (Figure 3D, E). These
findings indicate that the protective effect of PAF against LPS
lethalityresults from amarked decreaseinall characteristic ofsevere
tissue injury in LPS-induced endotoxemia. Extensive lymphocyte
apoptosis is critical pathogenic event in sepsis [5,17,18]. As such, it
was noteworthy to investigate whether exogenous PAF treatment in
endotoxemic mice exerts an inhibitory effect on apoptosis of
immune effector cells. Our in vivo studies demonstrate that PAF
inhibits T and B lymphocyte apoptosis in LPS-induced endotoxe-
mic mice (Figure 4), indicating that survival in endotoxin mice may
be improved by PAF treatment.
Collectively, our findings demonstrate the immunosuppressive
effects of exogenous PAF in containing the host immune response
to bacterial products. Present findings of unexpected pathophys-
iological PAF activities in the LPS-mediated endotoxic shock
suggest that the role of PAF in regulating the immune response
may be more complex beyond its established role as a pro-
inflammatory mediator. We speculate that PAF may be a
significant pharmacological target for treatment of patients with
endotoxic shock.
Materials and Methods
Animals
The animal protocol used in this study has been reviewed by the
Pusan National University–Institutional Animal Care and Use
Committee (PNU-IACUC) on their ethical procedures and
scientific care, and it has been approved (Approval Number
PNU-2008-0001).BALB/c mice at 7,8 wk of age were purchased
from the Korean Institute of Chemistry Technology (Daejeon,
Korea) and were used. The animals were housed in a specific
pathogen-free environment within our animal facility and used in
accordance with the institutional guidelines for animal care.
Reagents
PAF, carbamyl-PAF (cPAF), and BN-52021 were purchased
from Sigma-Aldrich.
LPS-induced endotoxemia model
For LPS-mediated endotoxemia models, mice were injected i.p.
with the designated dose of LPS (E.coli O127:B8, Sigma-Aldrich)
dissolved in PBS containing 0.25% bovine serum albumin (BSA).
The general conditions and mortality were recorded for up to 6 d
after injection to ensure that no additional late deaths occurred.
The designated doses of PAF were administered i.p. immediately
after LPS (20 mg/kg), unless otherwise stated. PBS containing
0.25% BSA was used as a control treatment.
Isolation of peritoneal macrophages and dendritic cells
To isolate elicited peritoneal macrophages, mice were injected
i.p. (2 ml/mouse) with 4% Brewer thioglycollate medium (Sigma-
Aldrich) and peritoneal exudate cells were harvested 3 d later.
DCs were generated from murine BM cells as described by
previously [25] with some modifications. In brief, BM was flushed
from the tibiae and femurs of Balb/c and depleted of red cells with
ammonium chloride. The cells were plated in six-well culture
plates (10
6 cells/ml; 3 ml/well) in RPMI-1640 medium (Hyclone)
plus 10% heat-inactivated FBS (Hyclone) and 20 ng/ml recom-
binant murine granulocyte-macrophage colony- stimulating factor
(rm GM-CSF) at 37uC, 5% CO2. On day 6, 80% or more of the
nonadherent cells expressed CD11c.
Measurement of Cytokines
Serum and culture supernatants of peritoneal macrophages or
BMDCs were collected and assayed for various cytokine levels
using enzyme-linked immunosorbent assay (ELISA). ELISA kits
were purchased from Assay Designs and R&D Systems.
Clinical Chemistry
Serum levels of aspartate transaminase (AST), alanine trans-
aminase (ALT), and blood urea nitrogen (BUN) activity were
measured by Laboratory Medicine, Clinical Pathology at Pusan
National University Hospital using Automatic Hematology
Analyzer (Hitachi modular system, Hitachi Ltd., Tokyo, Japan).
Measurement of PMN infiltration
Lungs were first perfused with 10% formalin at constant
distending pressure of 25 cm H2O for 10 min. Liver and lung
Effect of PAF on Endotoxemia
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overnight at 4uC. And then, these were tissues embedded in
paraffin and 4-mM sections were prepared and stained with
hematoxylin and eosin.
Myeloperoxidase (MPO) estimation
Neutrophil sequestration in lung, liver, and kidney was
quantified by measuring tissue MPO activity. Tissue Samples for
MPO analysis were frozen in liquid nitrogen immediately after
removal from the animal and were thawed, homogenized in
following lysis buffer: 200 mM NaCl, 5 mM EDTA, 10 mM Tris,
10% glycerol, 1 mM PMSF, 1 mg/ml leupeptide and 28 mg/ml
aprotinine (pH 7.4). Centrifuge samples twice (6,000 g at 4uC for
15 min) to avoid contamination of cell debri and the cleared
supernatant was used for the MPO assay. MPO activities were
measured using a mouse MPO ELISA kit (Hycult biotechnology
b.v., Uden, The Netherlands), according to the manufacturer’s
instructions. Protein concentration in the supernatants was
measured by protein dye binding assay (protein assay; Bio-Rad
Laboratories). The levels of MPO in organ extracts were expressed
as nanogram per milligram of protein.
Measurement of mean arterial blood pressure (MABP)
Under urethane anesthesia, we performed cannulation of the
carotid artery, and then, MABP of mice were monitored by laser-
Doppler flowmetry (FLO-N1, Omegawave, Tokyo, Japan).
Flow cytometry
Spleens were gently glass-ground to dissociate the cells. Cells
were then washed twice in PBS. Residual red blood cells were
lysed by hypotonic lysis in ice-cold ammonium chloride. The cells
were resuspended in PBS and the desired fluorescent indicators
added. The degree of apoptotic cell death was quantified using a
commercially available annexin V-FITC detection apoptosis kit I
(BD PharMingen, San Diego, CA, USA). Mouse T and B cells
were identified by fluorescently labeled mouse monoclonal
antibodies specific for the desired cell subtype (BD PharMingen).
Identification of apoptotic cells by annexin V staining and cell
phenotyping were done simultaneously using flow cytometry on a
FACS-Calibur (Becton Dickinson). Cell debris was electronically
gated out, based on forward light scatter.
TUNEL Assay
To detect apoptotic cells, fixed paraffin-embedded spleens were
labeled by the terminal deoxynucleotidyl transferase dUTP nick-
end labelling TUNEL assay using a commercially-available kit
from Upstate (Lake Placid, NY, USA) and were then examined by
laser scanning confocal microscopy.
Statistics
Experiments were repeated at least three times with consistent
results. Prism 4.0 (GraphPad Software) was used for tests. A two-
tailed, unpaired Student’s t-test with 95% confidence bounds was
used for statistical analysis unless otherwise indicated.
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